[1] |
Singaravelu K, Gácser A, Nosanchuk JD. Genetic determinants of virulence ⁃ Candida parapsilosis[J]. Rev Iberoam Micol, 2014, 31(1): 16⁃21. DOI: 10.1016/j.riam.2013.09.018.
|
[2] |
Diekema D, Arbefeville S, Boyken L, et al. The changing epidemiology of healthcare⁃associated candidemia over three decades[J]. Diagn Microbiol Infect Dis, 2012, 73(1): 45⁃48. DOI: 10.1016/j.diagmicrobio.2012.02.001.
|
[3] |
Silva AP, Miranda IM, Guida A, et al. Transcriptional profiling of azole⁃resistant Candida parapsilosis strains[J]. Antimicrob Agents Chemother, 2011, 55(7): 3546⁃3556. DOI: 10.1128/AAC. 01127⁃10.
|
[4] |
Berkow EL, Manigaba K, Parker JE, et al. Multidrug transporters and alterations in sterol biosynthesis contribute to azole antifungal resistance in Candida parapsilosis[J]. Antimicrob Agents Chemother, 2015, 59(10): 5942⁃5950. DOI: 10.1128/AAC.01358⁃15.
|
[5] |
Lockhart SR, Iqbal N, Cleveland AA, et al. Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population⁃based surveillance studies in two U.S. cities from 2008 to 2011[J]. J Clin Microbiol, 2012, 50(11): 3435⁃3442. DOI: 10.1128/JCM.01283⁃12.
|
[6] |
van Asbeck EC, Clemons KV, Stevens DA. Candida parapsilosis: a review of its epidemiology, pathogenesis, clinical aspects, typing and antimicrobial susceptibility[J]. Crit Rev Microbiol, 2009, 35(4): 283⁃309. DOI: 10.3109/10408410903213393.
|
[7] |
Li SX, Song YJ, Zhang LL, et al. An in vitro and in vivo study on the synergistic effect and mechanism of itraconazole or voriconazole alone and in combination with tetrandrine against Aspergillus fumigatus[J]. J Med Microbiol, 2015, 64(9): 1008⁃1020. DOI: 10.1099/jmm.0.000120.
|
[8] |
Guo H, Xie SM, Li SX, et al. Synergistic mechanism for tetrandrine on fluconazole against Candida albicans through the mitochondrial aerobic respiratory metabolism pathway[J]. J Med Microbiol, 2014, 63(Pt 7): 988⁃996. DOI: 10.1099/jmm.0.073890⁃0.
|
[9] |
Chaturvedi V, Ramani R, Andes D, et al. Multilaboratory testing of two⁃drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis[J]. Antimicrob Agents Chemother, 2011, 55(4): 1543⁃1548. DOI: 10.1128/AAC. 01510⁃09.
|
[10] |
Clinical and laboratory Standards Institute (CLSI). CLSI docu⁃ment M27⁃A3 reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard⁃third edition [S]. Wayne PA:Clinical and Laboratory Standards Institute, 2008.
|
[11] |
Li Y, Sun S, Guo Q, et al. In vitro interaction between azoles and cyclosporin A against clinical isolates of Candida albicans determined by the chequerboard method and time⁃kill curves[J]. J Antimicrob Chemother, 2008, 61(3): 577⁃585. DOI: 10.1093/jac/dkm493.
|
[12] |
Sun S, Li Y, Guo Q, et al. In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods[J]. Antimicrob Agents Chemother, 2008, 52(2): 409⁃417. DOI: 10.1128/AAC.01070⁃07.
|
[13] |
Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. by use of clinical and laboratory standards institute broth microdilution methods, 2010 to 2012[J]. J Clin Microbiol, 2012, 50(9): 2846⁃2856. DOI: 10.1128/JCM.00937⁃12.
|
[14] |
Milan EP, Burattini MN, Kallás EG, et al. Azole resistance among oral Candida species isolates from AIDS patients under ketoconazole exposure[J]. Diagn Microbiol Infect Dis, 1998, 32(3): 211⁃216. DOI: 10.1016/S0732⁃8893(98)00107⁃2.
|
[15] |
Wang H, Xiao M, Chen SC, et al. In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF⁃NET) study[J]. J Clin Microbiol, 2012, 50(12): 3952⁃3959. DOI: 10.1128/JCM.01130⁃12.
|